Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

2.420 -0.110 (-4.35%)

Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

What's Next: Seres Therapeutics's Earnings Preview ↗

November 12, 2024

Via Benzinga

This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

October 24, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 26, 2024

Via Benzinga

MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q2 2024 ↗

August 13, 2024

MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders

August 09, 2024

From Halper Sadeh LLC

Via Business Wire

Seres Therapeutics's Earnings: A Preview ↗

March 04, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 10, 2024

Via Benzinga

Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 07, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 07, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 09, 2024

Via Benzinga

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 08, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 08, 2024

Via Benzinga

MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024 ↗

May 08, 2024

MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Nasdaq Down Over 50 Points; Uber Posts Q1 Loss ↗

May 08, 2024

Via Benzinga

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 08, 2024

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 06, 2024

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

May 06, 2024

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

April 09, 2024

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 28, 2024

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 19, 2024

From Seres Therapeutics, Inc.

Via Business Wire

Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

March 06, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Gold Price Alert: Gold Spot Prices Just Hit a Record High Today ↗

March 05, 2024

Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally.

Via InvestorPlace

MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023 ↗

March 05, 2024

MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

March 05, 2024

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

February 28, 2024

From Seres Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For March 5, 2024 ↗

March 05, 2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.

Via Benzinga

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

February 27, 2024

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

February 26, 2024

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 17, 2024

From Seres Therapeutics, Inc.

Via Business Wire

Why Is Microbiome-Based Seres Therapeutics Stock Trading Higher Today? ↗

January 09, 2024

Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.